Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels in Red Blood Cells and Omega-3 Index
NCT ID: NCT01749202
Last Updated: 2012-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
126 participants
INTERVENTIONAL
2010-08-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Negative Control
Sunflower Oil Softgels
3 x 500 mg softgel capsules/day
Sunflower Oil Food
3 servings/day
Positive Control
EPA softgels
3 x 500 mg softgel capsules/day
Sunflower Oil Food
3 servings/day
Active
Sunflower Oil Softgels
3 x 500 mg softgel capsules/day
SDA soybean Oil Food
3 servings/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sunflower Oil Softgels
3 x 500 mg softgel capsules/day
EPA softgels
3 x 500 mg softgel capsules/day
Sunflower Oil Food
3 servings/day
SDA soybean Oil Food
3 servings/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI) ≥18.00 and \<40.00 kg/m2.
3. No health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history and routine laboratory test results.
4. Willing to avoid alcohol consumption for 24 h prior to every clinic visit.
5. No plans to change smoking habits during the study period.
6. Willing to maintain a stable body weight, activity level and dietary pattern except for use of the study products, as directed.
7. Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
Exclusion Criteria
* Diabetes mellitus
* Clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease
* Presence of multiple risk factors that give a person a greater than 20% chance for developing coronary artery disease within 10 years.
2. Abnormal laboratory test results of clinical significance
3. TG ≥400 mg/dL at visit 1, week -2.
4. Smokes more than one pack of cigarettes (20 cigarettes) per day.
5. History or presence of clinically important renal, hepatic, pulmonary, biliary, gastrointestinal, neurologic or endocrine disorders that in the judgment of the Investigator, would interfere with the subject's ability to provide informed consent, comply with the study protocol Stable, treated hypothyroidism is allowed.
6. Uncontrolled hypertension
7. Unstable use within four weeks of visit 1 (week -2) of antihypertensive medications or thyroid hormone replacement.
8. Use of any lipid-altering drugs, including statins, bile acid sequestrants, cholesterol absorption inhibitors, fibrates, or prescription formulations of niacin within four weeks of visit 1 (week -2) and throughout the study. If a subject needs to wash off of a drug, he/she will be consented and then asked to return after the four week washout.
9. Use of EPA/DHA from a drug or supplement within four months of visit 1
10. Frequent use (more than twice per month) of any non-study-related EPA/DHA containing enriched foods (such as DHA-enriched eggs) within four months of visit 1, week -2 and avoidance of these enriched foods throughout the study period
11. Use of seeds and oils containing a significant amount of ALA
12. Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, or sardines) more than twice per month
13. Use of any dietary supplement known to alter lipid metabolism
14. Use of any weight-loss medication
15. Use of any weight loss supplement or program within four weeks of visit 1
16. Known allergy or sensitivity to study products or any ingredients of the study products.
17. Subject is unwilling to consume the study products (bars, beverages and capsules) based on results from the taste testing of the study products at visit 1, week -2.
18. Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer
19. Females who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation.
20. Current or recent history of (within 12 months of visit 1, week -2) or strong potential for alcohol or substance abuse. Alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1 ½ oz distilled spirits).
21. Exposure to any non-registered drug product within 30 days prior to the screening visit (visit 1, week -2).
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Provident Clinical Research
OTHER
Solae, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ratna Mukherjea, PhD
Role: PRINCIPAL_INVESTIGATOR
Solae, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Provident Clinical Research &Consulting
Glen Ellyn, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRV-10001
Identifier Type: -
Identifier Source: org_study_id